**FR0010417345 - Common Stock **

We assign a fundamental rating of **2** out of 10 to **DBV**. **DBV** was compared to 49 industry peers in the **Biotechnology** industry. Both the profitability and financial health of **DBV** have multiple concerns. **DBV** has a expensive valuation and it also scores bad on growth

The profitability ratios for **DBV** are negative, so there is not much use analyzing them.

ROA (-142.57%) VS Industry: 6% outperformed.

-154.47

65.73

Profit Margin (-1519.59%) VS Industry: 25% outperformed.

-470,040.00

326,680.00

When comparing the price book ratio of **DBV** to the average industry price book ratio of 2.44, **DBV** is valued rather cheaply.

With a price book ratio of **1.29**, **DBV** is valued correctly.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **DBV**. No positive earnings are expected for the next year.

Price/Book (1.29) VS Industry: 66% outperformed.

13.43

0.01

Based on estimates for the next 5 years, **DBV** will show a small growth in **Earnings Per Share**. The EPS will grow by **2.93%** on average per year.

Looking at the last year, **DBV** shows a very negative growth in **Revenue**. The Revenue has decreased by **-49.38%** in the last year.

Based on estimates for the next 5 years, **DBV** will show a very negative growth in **Revenue**. The Revenue will decrease by **-14.87%** on average per year.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | N/A | N/A | 39.32% | 2.08% | 2.94% | -11.33% | 2.93% |

Revenue | -10.44% | -28.85% | -49.38% | -31.37% | -1.48% | -25.99% | -14.87% |

With a Debt to Equity ratio of **0.00**, **DBV** is doing better than the averages in the industry. The industry average is at **0.05**.

The Quick Ratio is in line with the industry averages, which is at **2.64**.

Based on the Altman-Z score of **-4.22**, we must say that **DBV** is in the distress zone and has some risk of bankruptcy.

Compared to an average industry Altman-Z score of **0.11**, **DBV** is in worse financial health than its industry peers.

Debt/Equity (0) VS Industry: 80% outperformed.

1.52

-7.86

Quick Ratio (3.26) VS Industry: 58% outperformed.

0.28

19.61

Current Ratio (3.26) VS Industry: 58% outperformed.

0.28

19.61

Altman-Z (-4.22) VS Industry: 24% outperformed.

-27.85

31.85

No dividends for **DBV**!.

EPA:DBV (5/17/2022, 7:00:00 PM)**+0.05 (+2.12%) **

GICS Sector | Health Care | ||

GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||

GICS Industry | Biotechnology | ||

Earnings (Last) | N/A N/A | Earnings (Next) | N/A N/A |

Ins Owners | N/A | Inst Owners | N/A |

Market Cap | 274.76M | Analysts | 70 |

PE | N/A | Fwd PE | N/A |

PEG (NY) | N/A | PEG (5Y) | N/A |

P/S | 28.61 | P/B | 1.29 |

EV/EBITDA | -1.93 |

ROA | -142.57% | ROE | N/A |

PM | -1519.59 | Asset Turnover | 0.08 |

EPS 1Y | 39.32% | EPS 3Y | N/A |

EPS 5Y | N/A | EPS growth Q2Q | 46.28% |

EPS Next Y | 2.08% | EPS Next 2Y | 2.94% |

EPS Next 3Y | -11.33% | EPS Next 5Y | 2.93% |

Revenue growth 1Y | -49.38% | Revenue growth 3Y | -28.85% |

Revenue growth 5Y | -10.44% | Revenue growth Q2Q | 44.43% |

Revenue Next Year | -31.37% | Revenue Next 2Y | -1.48% |

Revenue Next 3Y | -25.99% | Revenue Next 5Y | -14.87% |

Current Ratio | 3.26 | Quick Ratio | 3.26 |

Altman-Z | -4.22 | F-Score | 1 |

Debt/Equity | N/A |

Dividend Yield | N/A | Dividend Growth | N/A |

DP | N/A | Ex-Date | N/A |

*Find stocks with similar Fundamental rating on the EuroNext*

*Find the competitors with the best fundamentals on the EuroNext*

*Find the competitors with the best valuation on the EuroNext*

*Find the competitors with the best dividend on the EuroNext*